Reach Us +44-1235425476
Personalized Medicine And Quality Of Life In Oncology: Contributions From Nuclear Medicine | 46593
ISSN: 2155-9619

Journal of Nuclear Medicine & Radiation Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

Clinical Oncology & Radiation Therapy

Singapore, Singapore
Share This Page

Personalized medicine and quality of life in oncology: Contributions from nuclear medicine

International Conference on Nuclear Medicine & Radiation Therapy

Masha Maharaj

Umhlanga Molecular Imaging and Therapy Centre, South Africa

Posters & Accepted Abstracts: J Nucl Med Radiat Ther

DOI: 10.4172/2155-9619.C1.006

Nuclear Physician Specialist, Umhlanga Molecular Imaging and Therapy Centre Personalized medicine has shifted the paradigm of individualized patient management in evidence-based medicine. In the last 2 decades, advances in targeted radiotherapy have set the stage for a new group of targeting agents with promising performances. Specific imaging probes are the nuclear fuel for molecular imaging by Single Photon Emission Tomography (SPECT) or Positron Emission Tomography (PET). The non-invasive depiction and quantification of biochemical processes with the goal of functional characterization of tumor biology is critical toward the understanding of tumour behaviour. Interpreting and translating these imaging targets into targeting therapeutic agents (Theranostics) is fundamental in selecting alternative therapy options, predicting response in therapy and estimating therapeutic outcome, thus personalizing therapy on a molecular level. There has been increasing weight placed upon quantification of quality of life in the individual. Generally these agents are well tolerated without serious side effects. This has widened the impact and outcome of target radiotherapy and generated the theranostics era.

Email: [email protected]